$EyePoint Pharmaceuticals (EYPT.US)$Traders Circulate Unconfirmed Report On Social Media That Eyepoint Pharmaceuticals Received National Medical Products Administration Approval Of Dexycu In China To Treat Post-Operative Inflammation Following Ocular Surgery
1
1
Report
Daight
:
easy way to confirm just check if the boss is has any connections to CCP or not.
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER...
131
6
6
Report
iluvpoptarts
:
ty much. I owe you a good joke when you're ready
Arrayfunction
:
This is probably an unknowable question - but logically, the massive cuts at NIH and NSF are going to stall out the biotech industry with what.....an 8-10 year lag? I know they don't tend to fund private clinical trials all that often, but they are shutting the tap off at the academic institutions that come up with the molecules that biotech/pharma buys the rights to?
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, ...
IamBadNewz
:
@Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If...
FernandoTrades
:
not trying to post my own watchlist or anything just looking for advise. All these stocks have there earning reports come out tmr and I was wondering if you think there good or not.
Jaguar8
OPHannChau
:
If Trump imposes tariffs or restrictions on steel and aluminum imports, U.S. steel stocks could see a short-term boost as domestic producers benefit from reduced foreign competition. Higher import costs might lead to increased demand for American-made steel, potentially driving up prices and improving profit margins forcompanies like NUE, X, and CLF. However, industries reliant on steel, such as automotive and construction, could face higher costs, which might eventually reduce demand. Investors should watch for potential retaliation from trade partners, as countermeasures could offset some gains.
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
4
Report
HannChau
:
I will not be silent stalker but always will be voice out 'stalker'
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, ...
57
12
1
Report
74537207
:
thank you very much , I am starting to miss your 'mega' picks a bit
$EyePoint Pharmaceuticals (EYPT.US)$ EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept...
3
3
Report
105475071
:
Hello, why does this Stocks fall immediately after rising?
Jaguar8
OP105475071
:
During pre market where there is less or low liquid volatility, a large sell off can cause it to drop or short sell pressure can cause it to drop too
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
EyePoint Pharmaceuticals Stock Forum
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept...
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds
EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses
No comment yet